Trisenox (arsenic trioxide) may have some efficacy in the treatment of myelodysplastic syndromes (MDS), according to a Phase 2 study conducted by Italian researchers.
The findings were presented at the 51st annual American Society of Hematology (ASH) Meeting and Exposition in New Orleans on December 8.
Trisenox is an FDA-approved therapeutic agent for the treatment of certain types of leukemia. It is currently being studied for use in the treatment of high- and low-risk MDS. In vitro studies, which are…
Revlimid (lenalidomide) given at a dose of 10 mg may be the most effective initial dose for the treatment of myelodysplastic syndromes (MDS), according to the results of a Phase 3 study conducted by a team of international researchers. The findings were presented at the 51st Annual American Society of Hematology (ASH) meeting and exposition on December 8.
For MDS, Revlimid is typically used as a treatment for low- or intermediate-1 risk patients, especially those who require red blood cell…
The dosing schedule of Vidaza (azacitidine) currently approved for use in Europe may be the most effective and safest treatment plan for myelodysplastic syndromes (MDS) compared with alternative dosing schedules according to a retrospective analysis of clinical results collected by Spanish researchers. The findings were presented at the 51st Annual American Society of Hematology (ASH) meeting and exposition on December 5.
Vidaza is one of several newly approved drugs for the treatment of MDS. Clinical trial data indicates that Vidaza typically delays progression of…
Clolar (clofarabine) may be effective in the treatment of high-risk myelodysplastic syndromes (MDS), according to a recent article reviewing studies of Clolar in the treatment of leukemia and related conditions.
The article, which was published in the journal Expert Opinion on Investigational Drugs, summarized current developments in the study of Clolar, especially for elderly acute myeloid leukemia (AML) patients. Summaries of several studies involving the use of Clolar in MDS patients were also included.
Clolar works by inhibiting DNA synthesis,…